NEW YORK, Feb. 9, 2007 (PRIME NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Alan G. Harris, MD, PhD, the company's Chief Medical Officer, will co-chair the upcoming two-day conference on Drug Development for Obesity: Key Strategies for Effective Drug Discovery. The event will be held February 12-13 at the Kensington Marriott Hotel in London, UK.
In addition to his leadership responsibilities at the conference, Dr. Harris will also give a presentation titled: "Obesity: An Underlying Cause of the Metabolic Syndrome" which will be held Tuesday, February 13 at 9:50am GMT.
Keynote speakers to be featured at the conference include Prof. Jon Arch, University of Buckingham and Prof. Steve Bloom, Imperial College London. Other expert speakers include Dr. Joannes Linders, Johnson & Johnson; Dr. Antonio Tataranni, sanofi-aventis; Dr. Rafaella Balena, Hoffman La-Roche, and many other industry experts from companies involved in leading obesity research.
To learn more about the conference, or to request a brochure, please go to http://www.marcusevans.com/events/CFEventinfo.asp?EventID=11707 or visit the Manhattan Pharmaceuticals, Inc. website at http://www.manhattanpharma.com.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc., a development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for the treatment of both common obesity and morbid obesity. To meet the needs of other major, underserved medical markets Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis, and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (http://www.manhattanpharma.com)
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Manhattan Pharmaceutical's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that Manhattan will be able to regain compliance with AMEX's continued listing standards. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Manhattan's product candidates, the risk that the results of clinical trials may not support Manhattan's claims, Manhattan's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2005. Manhattan assumes no obligation to update these statements, except as required by law.